Deciphera Pharmaceuticals LLC

82 articles with Deciphera Pharmaceuticals LLC

• Deciphera Pharmaceuticals, Inc. Announces Appointment of Susan L. Kelley, M.D., to its Board of Directors

  7/8/2019

  Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the appointment of Susan L. Kelley, M.D. to its Board of Directors

• Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China

  6/11/2019

  Deciphera Intends to Expand Ripretinib Development Program in Gastrointestinal Stromal Tumors (GIST) by Potentially Adding China Sites to the Ongoing Global Phase 3 INTRIGUE Study

• Deciphera Pharmaceuticals, Inc. Expands Pipeline with Potential First-in-Class Autophagy Inhibitor to Treat Mutant RAS Cancers

  6/10/2019

  Company to Host a Webcast on Tuesday, June 18, 2019 at 8 a.m. ET to Discuss Autophagy Inhibition and the Treatment of Mutant RAS Cancers

• Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Global Healthcare Conference

  5/30/2019

  Deciphera Pharmaceuticals, Inc. announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 6 at 1:30 PM ET in New York City.

• Deciphera Pharmaceuticals, Inc. to Present at the UBS Global Healthcare Conference

  5/14/2019

  Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the UBS Global Healthcare Conference on Monday, May 20 at 9:00 AM ET at the Grand Hyatt New York.

• Deciphera Pharmaceuticals, Inc. Announces First Quarter 2019 Financial Results

  5/9/2019

  Deciphera Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2019 and provided an update on clinical and corporate developments.

• Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Year-end 2018 Financial Results

  3/14/2019

  Enrollment Completed in INVICTUS Pivotal Phase 3 Clinical Study in Fourth-line and Fourth-line Plus GIST; Top-line Data Expected in Mid-2019

• 

  Former Agios Executive to Take Over Deciphera After CEO Steps Down

  3/5/2019

  After five years at the reins, Mike Taylor will step down from his role as president and chief executive officer of Waltham, Mass.-based Deciphera Pharmaceuticals. Taylor’s last day in the role will by March 18, the company announced late Monday.

• Deciphera Pharmaceuticals, Inc. Announces Retirement of Michael D. Taylor, Ph.D.

  3/4/2019

  Current Deciphera Director and Experienced Commercial Oncology Executive, Steve Hoerter, Appointed as New President & Chief Executive Officer

• Deciphera Pharmaceuticals, Inc. to Present at the 1st Annual Guggenheim Healthcare Talks Idea Forum Oncology Day

  2/7/2019

  Deciphera Pharmaceuticals, Inc. announced that Michael Taylor, Ph.D., President and Chief Executive Officer, will present at the 1st Annual Guggenheim Healthcare Talks Idea Forum Oncology Day on Thursday, February 14 at 3:30 PM ET at the St.

• Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Carboplatin in Patients with Advanced or Metastatic Solid Tumors

  1/3/2019

  Rebastinib is a Potent and Selective Inhibitor of the TIE2 kinase, the Receptor for Angiopoietins, an Important Family of Vascular Growth Factors Involved in Tumor Growth, Survival and Metastasis

• Deciphera Pharmaceuticals Announces Positive, Preliminary, Top-Line Clinical Data for the Ongoing Phase 1 Clinical Study with DCC-3014 and an Update on Future Development Plans

  1/2/2019

  DCC-3014, A Highly-Selective and Potent Small Molecule Inhibitor of CSF1R, Demonstrates Tolerability, Pharmacokinetics and Biomarker Mechanistic Proof-of-Concept (mPoC) in Patients with Advanced Malignancies

• Deciphera Pharmaceuticals, Inc. to Present at the 37th Annual J.P. Morgan Healthcare Conference

  1/2/2019

  Deciphera Pharmaceuticals, Inc. today announced that Michael D. Taylor, Ph.D., President and Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 at 2:00 PM PT at the Westin St. Francis in San Francisco.

• Deciphera Pharmaceuticals Initiates Pivotal Phase 3 Clinical Study of Ripretinib (DCC-2618) in Second-line Patients with Gastrointestinal Stromal Tumors (“INTRIGUE” Study)

  12/20/2018

  The Efficacy and Tolerability Profile of Ripretinib Will Be Compared to Sunitinib in Second-line GIST Patients Regardless of KIT or PDGFRα Mutational Status

• Deciphera Pharmaceuticals, Inc. to Present at the 30th Annual Piper Jaffray Healthcare Conference

  11/20/2018

  30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 2:30 PM ET at the Lotte New York Palace

• Deciphera Pharmaceuticals Completes Enrollment in the INVICTUS Pivotal Phase 3 Clinical Study of DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors

  11/15/2018

  - Company Expects to Report Top-line Data in Mid-2019 and is Building the Commercial Capabilities to Support the Planned Launch of DCC-2618 in the United States -

• Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2018 Financial Results

  11/8/2018

  Preliminary Phase 1 Clinical Study Results Presented at the European Society of Medical Oncology (ESMO) 2018 Congress Demonstrate the Potential of DCC-2618 to Provide Improved and Durable Clinical Outcomes in Second- and Third-Line Patients

• Deciphera Pharmaceuticals Initiates a Phase 1b/2 Clinical Trial of Rebastinib in Combination with Paclitaxel to Assess Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced or Metastatic Solid Tumors

  10/23/2018

  Rebastinib is a Potent and Selective Inhibitor of the TIE2 kinase, the Receptor for Angiopoietins, an Important Family of Vascular Growth Factors in the Tumor Microenvironment

• Deciphera Pharmaceuticals Reports Updated Preliminary Phase 1 Clinical Study Results with DCC-2618 at the European Society of Medical Oncology (ESMO) 2018 Congress

  10/19/2018

  Preliminary Median Progression Free Survival and Disease Control Rates from the Phase 1 Study of DCC-2618 in Second- and Third-Line GIST Patients Demonstrate the Potential for Improved and Durable Clinical Outcomes in Patients with Less Advanced Disease

• Deciphera Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference

  9/25/2018

  Deciphera Pharmaceuticals, Inc. today announced that Michael Taylor, Ph.D., President and Chief Executive Officer, will present at the 2018 Cantor Global Healthcare Conference on Tuesday, October 2, 2018 at 4:00 PM ET at the InterContinental New York Barclay Hotel.